NCT00660257View on ClinicalTrials.gov

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2008

Conditions
Pandemic Influenza VaccinePreventionPandemic Influenza
Interventions
BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection

BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection

BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection

BIOLOGICAL

pandemic influenza vaccine (H5N1 strain NIBRG-14)

pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection

Trial Locations (1)

Unknown

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention, China

OTHER_GOV

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT00660257 - Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine | Biotech Hunter | Biotech Hunter